Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus MIVACURIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus MIVACURIUM CHLORIDE.
ARDUAN vs MIVACURIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Mivacurium chloride is a non-depolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor end-plate, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission. It is a mixture of stereoisomers and is rapidly hydrolyzed by plasma cholinesterase.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
0.15-0.25 mg/kg IV bolus for endotracheal intubation; maintenance infusion: 0.5-1.5 mcg/kg/min IV
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Terminal elimination half-life is approximately 2 minutes (range 1-3 minutes) for the initial rapid distribution phase, and the elimination half-life is about 17-20 minutes in patients with normal renal function. Clinically, this short half-life allows for rapid recovery of neuromuscular function.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Primarily renal excretion of unchanged drug and metabolites; approximately 90-95% eliminated via urine, with less than 5% in feces. Minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker